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BACKGROUND: Approximately 4% of patients diagnosed with early breast cancer have occult metastases at presentation. Current
national and international guidelines lack consensus on whom to image and how.
METHODS: We assessed practice in baseline radiological staging against local guidelines for asymptomatic newly diagnosed breast
cancer patients presenting to the Cambridge Breast Unit over a 9-year period.
RESULTS: A total of 2612 patients were eligible for analysis; 91.7% were appropriately investigated. However in the subset of lymph
node negative stage II patients, only 269 out of 354 (76.0%) investigations were appropriate. No patients with stage 0 or I disease had
metastases; only two patients (0.3%) with stage II and p3 positive lymph nodes had metastases. Conversely, 2.2, 2.6 and 3.8% of
these groups had false-positive results. The incidence of occult metastases increased by stage, being present in 6, 13.9 and 57% of
patients with stage II (X4 positive lymph nodes), III and IV disease, respectively.
CONCLUSION: These results prompted us to propose new local guidelines for staging asymptomatic breast cancer patients: only clinical
stage III or IV patients require baseline investigation. The high specificity and convenience of computed tomography (chest, abdomen
and pelvis) led us to recommend this as the investigation of choice in breast cancer patients requiring radiological staging.
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Breast cancer is second only to lung cancer in worldwide
prevalence. It represents 16% of all UK cancers and is the most
common cancer in women, accounting for 31% of all cancers
(WHO, 2003, 2006). The incidence of breast cancer amongst
women in the UK was 45 660 in 2005 (ONS, 2008). Approximately
4% of breast cancer patients will have detectable metastatic disease
at the time of diagnosis; the majority of these patients will have
signs or symptoms of metastases (Ravaioli et al, 2002). The most
common first sites of distant metastases are bone, lung, brain and
liver; up to 10% of patients with metastatic disease will have
lesions at multiple sites (Patanaphan et al, 1988). Conventionally,
high-risk patients have been screened for occult metastases in
these organs by using chest radiographs (CXR), liver ultrasound
(US) and bone scintigraphy (BS) (Puglisi et al, 2007). More
recently, techniques such as computed tomography (CT), magnetic
resonance imaging and 18FDG-positron emission tomography
(Avril et al, 2007) have started to be used in certain circumstances,
or for problem-solving.
The likelihood of detecting metastatic disease at the time of
initial diagnosis is highly dependant upon the extent of loco-
regional disease and the presence of symptoms. The detection of
such metastases has a profound effect upon patient management
and prognosis, however, there is little evidence to guide decisions
on which patients should be staged. Where symptoms are
suggestive of metastatic disease, appropriate investigations
targeted to the respective organs should be instigated. However,
the vast majority of newly diagnosed patients do not exhibit
symptoms or signs of metastatic disease. As metastatic rates overall
are so low, staging all patients would result in unacceptable
expenditure, increased workload, patient anxiety and radiation
burden. Imaging staging of patients needs to be targeted towards
those most likely to have disseminated disease. The aim of this paper
was to assess practice in baseline radiological staging against local
guidelines of a large cohort of breast cancer patients stratified by
clinico-pathological stage and additionally determine the likelihood
of detecting metastases and, as importantly, obtaining a false-
positive result. We also aimed to explore the current trend to use CT
rather than conventional assessment with CXR, US liver and BS.
MATERIALS AND METHODS
A list of all female patients diagnosed with breast cancer during a
9-year period, between 1 January 1999 and 31 December 2007, was
obtained from the Eastern Cancer Registration and Information
Centre (ECRIC) database. Each patient was prospectively allocated
a clinico-pathological staging classification by the ECRIC medical
director and clinical oncologist (author CHB). The classification
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was undertaken 6 months following initial diagnosis by reviewing
the medical records and was based on clinical, imaging and
pathological data. The overall distribution of patients between
stages is comparable to data published by the National Cancer
Data Base, USA (Table 1).
Staging was allocated according to the TNM (tumour, node,
metastasis) staging system (0–IV) published in the American Joint
Committee on Cancer (AJCC) staging manual. The AJCC sixth
edition was published in 2002 (Greene et al, 2002), replacing the
fifth edition from 1997 (Fleming et al, 1997) and contained some
changes particularly relevant to our study. In the sixth edition
‘N stages’ were changed to give greater emphasis to the number of
nodes involved: 4–9 nodes (or any internal mammary lymph
nodes) became N2 disease, and X10 axillary nodes now qualified
as N3 disease. N1 disease classifies the patient as stage II, whereas
N2 or N3 disease places a patient in the stage III category
(Supplementary Table 1). For example, patients with four positive
axillary lymph nodes would be stage IIb using the criteria of the
fifth edition, but stage IIIa under the sixth edition. To avoid
confusion, we retained the criteria used in the fifth edition, but
subdivided our results for stage II disease into patients with three
nodes or less (stage II-i) or more than four nodes (stage II-ii)
involved. It should be noted that patients with N1 status can still
have stage III or IV disease, if the tumour is 45 cm diameter, or
involves the skin or chest wall.
Patients in whom an accurate stage could not be defined due to
insufficient information and patients with symptoms, signs or
abnormal blood work indicative of metastatic disease were
excluded from the data analysis. The Cambridge Breast Unit is a
tertiary referral centre and treats some patients initially diagnosed
with breast cancer at another centre. As an accurate investigation
history could not always be reliably obtained, patients that did not
receive their primary diagnosis of breast cancer at this institution
were also excluded. The final exclusion criteria included patients
whose breast cancer was diagnosed on the basis of co-incidental
abnormal imaging results that suggested metastases and the search
for a primary cancer ensued.
With clinical stage being assigned retrospectively, 6 months
after diagnosis, patients where imaging had shown metastases were
classified as stage IV, however these patients may have initially
presented with a lower stage of disease clinically. Thus all stage IV
cases were reviewed on an individual basis and patients were
re-assigned to the relevant lower stage group based on the
information that would have been available at presentation.
It should be noted that patients can still present with clinical
stage IV disease, for example inflammatory breast cancer, thus
seven patients remained in this group following the application of
exclusion criteria and stage re-assignment.
Baseline staging investigations were arbitrarily chosen to be
those taking place within 3 months of the date of breast cancer
diagnosis. This was considered to be a reasonable time period for
management to be discussed in multi-disciplinary meetings,
surgery to take place, and histopathological results to be available
and subsequent imaging tests to be performed. Patients were
analysed on a case-by-case basis, with imaging investigations,
indications and results logged. A true-positive result was
determined as being one that unequivocally confirmed metastatic
disease on the basis of the respective imaging investigation
(Figure 1), or one that was proven by subsequent imaging or
histology (Figures 2 and 3). A false-positive result was taken as
being any staging investigation that was initially reported as being
either abnormal or indeterminate, but upon subsequent investiga-
tion(s) was proven to be negative (Figure 4).
The local staging guidelines at the Cambridge Breast Unit
(updated in 1999) used as the ‘gold standard’ for our assessment
are as follows:
 Pre-operative CXR is not necessary as a staging investigation
unless past medical history warrants, or symptoms warrant or
there is a high risk of an ITU admission (reference Making the
Best Use of a Department of Clinical Radiology, Royal College of
Radiologists)
 Patients with T4 tumours or malignant lymphadenopathy
should be considered for pre-operative staging with CXR, liver
US and bone scan
 Patients with more locally advanced breast cancer should have
investigations directed at findings underlying asymptomatic
metastases where this may influence management
Thus, patients with positive lymph nodes or T4 tumours
(involvement of chest wall or skin) are eligible for baseline staging
investigations according to local guidelines. This includes all
tumours that are N1–3 and/or T4 and any request for CXR, bone
scan, US or CT in such patients was considered appropriate.
However, staging was not deemed appropriate in stage 0, I and
stage II lymph node negative patients; a CXR for pre-operative
assessment was considered appropriate if indicated under the RCR
guidelines (RCR, 2007).


















0 432 12.7 348 13.3 57 796 17.1
I 1155 34 992 38 140 122 41.4
II 1388 40.8 1041 39.8 106 116 31.3
III 244 7.2 224 8.6 22 758 6.7
IV 145 4.3 7 0.3 11 780 3.5
Unknown 34 1 0 0 0 0
Overall 3398 100 2612 100 338 572 100
Abbreviation: NCDB¼National Cancer Data Base. Inclusion criteria: female patients
with a new diagnosis of breast cancer established between 1 January 1999 and 31
December 2007. Exclusion criteria: diagnosis not established at Addenbrooke’s, or
accurate stage could not be established – see text for full explanation. Reports, v1.1.
Chicago, IL, 2002. http://www.facs.org/cancer/ncdb/publicaccess.html. aComparative
figures taken from the National Cancer Data Base, USA 1998–1999: cases diagnosed
in 1247 US nationwide hospitals in 1998 and 1999: Commission on Cancer,
American College of Surgeons. NCDB Benchmark.
Figure 1 An ‘unequivocal’ true positive. Chest X-ray showing multiple
metastases throughout both lungs in a patient with stage IV breast cancer.
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Finally we estimated the health-care costs of detecting
metastases by stage of disease and mode of imaging staging. This
was based on local costing taking into consideration staffing,
consumable and hardware expenses. From the true-positive rates
achieved in this study we have calculated how much would need to
be spent to detect a single patient with metastatic disease for each
disease stage. These estimates have been made for staging by both
standard (CXR d80, US liver d176 and BS d184) methods and for
CT alone (chest, abdomen, pelvis d271). We have also included in
all these estimates the cost of additional imaging generated by the
false-positive results in this study.
RESULTS
Of 3398 patients with newly diagnosed breast cancer over the
9-year study period, 2612 cases were eligible for data analysis
(Table 1). Appropriate investigations undertaken in stages 0, I, and
II-i (stage II with p3 lymph nodes), that is patients who should
receive only a CXR (if clinically indicated) and no additional
staging investigations according to local guidelines, were as
follows: 325 out of 348 (93.4%) for stage 0, 881 out of 992 for
stage I (88.8%) and 779 out of 859 for stage II-i (90.7%). For the
subgroup of stage II-i with no lymph nodes involved only 269 out
Figure 2 True positive. Chest X-ray reveals a ‘coin’ lesion in the left mid-zone (A), also demonstrated on the lateral radiograph (B). CT examination (C)
on lung-window settings supports the diagnosis of a likely lung metastasis, later confirmed by CT-guided biopsy, performed with the patient lying prone (D).
Figure 3 True positive. Stage IV breast cancer patient. Ultrasound liver shows irregular lesions within the liver (A), subsequent CT (B) confirms liver
metastases, ascites also demonstrated.
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of 354 requests (76.0%) were appropriate. Overall for stages 0, I
and II-i, 1985 out of 2199 (90.3%) patients were appropriately
investigated. Including the 413 patients with stages II-ii, III and
IV disease, who were all appropriately investigated, the overall
compliance with local guidelines for baseline screening in
asymptomatic breast cancer patients was 2398 out of 2612 (91.8%).
Of the 1340 patients with stages 0 and I (674 of whom had a
least one investigation) there were no true-positive results but 17
patients had false-positive results. Of the 859 patients with
stage II-i disease there were only 2 potential true-positive results
(0.3% of cases). The majority (607) of these patients had at least
one investigation, and there were 23 (2.7%) false-positive results in
this group. There were 10 (6%) true-positive results and 22 (13.1%)
false-positive results in patients with stage II-ii; 26 (13.9%) true
positives and 24 (12.8%) false positives in stage III and 4 (57%)
true positives, with no false-positive results in patients with stage
IV disease (Table 2).
The two potential ‘true’-positive results in stage II-i patients
require further explanation. The first patient was 87 years old at
diagnosis and presented with a 22mm, node negative, grade 2
tumour. A soft tissue lesion was seen in the right lower zone on
baseline CXR and reported as representing a metastasis and
therefore classified as a true positive in this study. However,
6 years after initial presentation, a repeat CXR showed that the
lesion had not changed in size thus casting doubt over the initial
malignant diagnosis (Figure 5). In the interest of consistency we
have retained the initial classification for our analysis, however it
is possible that this represents a false- rather than true-positive
case. The second true-positive patient in the stage II-i group was 62
years old at diagnosis, and presented with a 38mm, node negative,
grade 3 tumour. Chest radiographs suggested lung metastases,
subsequently confirmed at CT, which additionally showed
Figure 4 False positive. Bone scintigram (A) and CT chest examination (B, C, D) in a patient with stage IV breast cancer. The bone scan was reported as
showing hot spots in the T10 vertebrae, left posterior seventh and right anterior second ribs, consistent with metastases. The follow-up CT scan revealed
these changes to be due to rib fractures (B), and degenerative disease (C, D) only.
Table 2 Number of investigations performed by modality and stage of
disease and true- and false-positive results by stage of disease
Stage 0 I II-i II-ii III IV Total
Total no. of patients 348 992 859 182 224 7 2612
Staging investigations
CXR 136 527 580 148 160 5 1556
US 0 19 101 100 114 5 339
BS 0 22 109 113 125 4 373
CT 3 6 19 15 34 1 78
Total no. of patients having staging investigations
True +ve (%) 0 (0) 0 (0) 2 (0.3) 10 (6) 26(13.9) 4 (57)
False +ve (%) 3 (2.2) 14 (2.6) 23 (3.8) 22 (13.1) 24 (12.8) 0 (0)
Abbreviations: BS¼ bone scintigraphy; CT¼ computed tomography; CXR¼ chest
radiograph; US¼ ultrasound. Stage II-i¼ patients with stage II disease by AJCC sixth
edition (Greene et al, 2002): p3 lymph nodes positive, stage II-ii¼ patients with
stage II disease by AJCC fifth edition (Fleming et al, 1997), but stage III disease by
AJCC sixth edition, i.e. X4 positive lymph nodes.
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peritoneal metastases. The patient was a smoker with a history of
hypertension, thus met local guidelines for a pre-operative CXR.
A subsequent clinic letter documented erythema and thickening of
the axilla; skin involvement would make the tumour T4 (stage
IIIb), thus it is possible that this case represents an error in stage
assignment.
There was a difference in the accuracy of the four different
imaging modalities used. There were 3 true-positive (0.2%) and 20
(1.3%) false-positive results out of 1556 CXRs, 6 true-positive
(1.8%) and 13 (3.8%) false-positive results out of 339 liver US, 23
true-positive (6.2%) and 51 (13.7%) false-positive results out of
373 bone scans, and 21 true-positive (26.9%) and 3 (3.8%) false-
positive results out of 78 CTs (Table 3). Computed tomography
was the only modality in which the percentage of true-positive
results was higher than the false-positive results. Computed
tomography also had a lower rate of false-positive results (3.8%)
than US and BS. Of the three false-positive CT results two
described small pulmonary nodules of indeterminate significance,
which were unchanged on follow-up CT, and one described a liver
lesion that was too small to characterise, but was shown to be a
cyst on subsequent US. There was a noticeable trend during the
study period to request more CT scans, with a corresponding
reduction in requests for CXR, US and bone scans.
In this review there were 23 patients with true-positive bone
scan results; of these every case had at least one metastasis in the
field that would be covered by CT of the chest/abdomen/pelvis.
Retrospective analysis of all bone scan results (including some
symptomatic patients who were later excluded) revealed that of
411 scans performed, 257 were normal, 41 showed degenerative
change, 52 were true-positive results and 61 were false-positive
results. In the 52 cases where the bone scan was found to be a true
positive, all patients had at least one metastasis within the field that
would be covered by CT of the chest, abdomen and pelvis.
The estimated health-care cost of detecting metastases by stage
of disease and mode of imaging staging is shown in Table 4.
Calculations were carried out on the true-positive rates and the
added expense generated by false-positive imaging results. The
CXR, BS and liver US false-positive rates in this study were 1.3,
13.7 and 3.8% respectively. Every false-positive CXR, BS and US
cost d89, d132 and d190, respectively, in additional imaging
investigations. The CT false-positive rate was 3.8% and every false-
positive CT costs d203 in additional imaging investigations. As no
metastatic disease was detected in any patient with stage 0 or I
disease the theoretical cost of detecting a metastasis was infinity.
The cost of detecting one true-positive in patients with stage II-i
disease (d200 393 by standard staging) is substantially higher than
for stage II-ii patients (d8492); thereafter, the cost of detecting a
metastasis continues to fall with increasing stage. It can also be
seen that there is an overall cost saving if CT is used to replace the
standard combination of CXR, BS and US.
DISCUSSION
We assessed local practice for the radiological staging of women
presenting with a new diagnosis of breast cancer, without
symptoms of metastases, over a 9-year period. Overall, the yield
for detecting metastases is low in such asymptomatic patients, with
no occult metastases detected in any patient with stage 0 or I
disease. Furthermore, only two patients with stage II-i disease had
possible evidence of occult metastases. In fact, in patients with
stage 0 to II-i such screening is likely to lead to a greater degree of
false-positive results: 40 (out of the 2199 patients). The yield is
improved in those presenting with a higher stage of disease: 40 out
Figure 5 One of two patients with stage II-i disease with a ‘true-positive’ diagnosis. The soft tissue lesion in the right lower zone was reported as being a
metastatic lesion on baseline CXR shortly after the patient presented with primary breast cancer in 2001 (A). However, in 2007 the lesion had not
significantly changed in size (B) and was retrospectively described as being ‘unlikely to be malignant’.
Table 3 True- and false-positive results by modality (includes all stages
of disease)
CXR US BS CT
Total 1556 339 373 78
True +ve (%) 3 (0.2) 6 (1.8) 23 (6.2) 21 (26.9)
False +ve (%) 20 (1.3) 13 (3.8) 51 (13.7) 3 (3.8)
Abbreviations: BS¼ bone scintigraphy; CT¼ computed tomography; CXR¼ chest
radiograph; US¼ ultrasound.
Table 4 Estimate of health-care costs to detect metastases by stage of
disease and by mode of imaging
TNM stage




0 0 0.2 5.5 11.6 57.0




Infinite Infinite d200 393 d8492 d4021 d817
CT staging alone Infinite Infinite d119 744 d5074 d2405 d488
Abbreviations: BS¼ bone scintigraphy; CT¼ computed tomography; CXR¼ chest
radiograph; TNM¼ tumour, node, metastasis; US¼ ultrasound. Estimates for
detecting a single patient with metastatic disease for each disease stage based on
local costings and the respective true- and false-positive rates by modality (see text
for costing estimates).
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of 413 patients with stage II-ii, III, or IV disease had true-positive
results (vs 46 false positives). These results show the benefit of a
risk-stratified staging protocol for early breast cancer but under-
line the importance of making inclusion criteria clear and less
open to interpretation. In this way the majority of occult
metastases can be detected with minimal false positives, incidental
findings and unnecessary radiation exposure.
The local guidelines for our review were, in retrospect, non-
specific and open to interpretation. Although the inclusion of
patients with T4 disease or any evidence of malignant lymphade-
nopathy is very clear, the inclusion of ‘patients with more locally
advanced disease’ is open to interpretation. In fact both national
and international guidelines on the baseline imaging of breast
cancer tend to be either open to interpretation or lack consensus.
NICE guidelines from 2002 recommend that patients with T4
tumours (stage IIIþ ) should have staging investigations, their
2009 update additionally accepts that there is currently insufficient
evidence to support the choice of one imaging modality over
another (NICE, 2002, 2009). The Scottish Intercollegiate Guidelines
Network also states that only stage IIIþ may require staging
(SIGN, 2005). The National Comprehensive Cancer Network
guidelines suggest that staging investigations are not required in
asymptomatic stage I disease, nor many other patients with early
stage breast cancer, and should only be considered in those with
symptoms or T3, N1, M0 disease (stage IIIa) (NCCN, 2009).
Conversely, the British Association of Surgical Oncology states
that no asymptomatic patients should be staged, aside from
pre-operative CXR (BASO, 2005).
These varying recommendations for imaging staging for occult
metastases in women with newly diagnosed breast cancer reflect
the paucity of evidence on this issue in the setting of early stage
disease without symptoms suggestive of metastases. Internation-
ally, the most robust guidelines seem to be those proposed by the
Cancer Care Ontario Practice Guidelines Initiative (CCOPGI)
(Myers et al, 2006). These guidelines are also endorsed by the
National Guideline Clearinghouse – an initiative of the Agency for
Healthcare Research and Quality which is affiliated with the
American Medical Association and America’s Health Insurance
Plans. The guidelines are based on a literature search of peer-
reviewed articles on the baseline investigation of asymptomatic
breast cancer patients up to 2003. They recommend no investiga-
tions for stage 0 and I patients, a BS for stage II disease and CXR,
US and BS for stage III tumours.
Having decided which patients to investigate, it is then
important to consider which modality or modalities are most
appropriate for radiological staging. The trend we have
observed locally is to move away from the more traditional
methods of investigation with CXR, US and BS, to use CT of the
chest, abdomen and pelvis. Certainly the CT option is
logistically easier for the patient – it involves one visit to the
department and the images can be acquired in a matter of
seconds. If patients are required to have a CXR, US and BS, this
will often involve separate attendances (often on separate days) to
different areas of the hospital and, in the case of bone scan,
returning 4 h after initial injection of isotope to complete the
study. Indeed, a study into patient preference comparing CT with
BS revealed that 75% patients preferred their experience of CT,
compared with only 5% at BS (20% no preference) (Groves et al,
2006). There is no question that CT chest is more sensitive and
specific than CXR for diagnosing lung metastases, nevertheless, it
does provide an increased radiation burden. Overall CT
probably has a higher sensitivity than US for liver lesion detection.
However, US will retain a role in targeting the biopsy of
indeterminate lesions, or evaluation of lesions too small to
characterise by CT.
Perhaps more controversial is the use of CT instead of BS.
Computed tomography advances enable improved detection of
bone metastases and there is evidence that this is equivalent to BS,
with some authors concluding that the latter may be omitted
(Groves et al, 2006; Bristow et al, 2008). Bone scintigraphy
covers the entire skeleton (including long bones, neck and skull),
however, of the 52 true-positive bone scan results in our study all
had at least one metastasis within a field that would be covered by
CT chest/abdomen/pelvis. Furthermore, detection of bone metas-
tases at an asymptomatic stage has not been shown to prolong
survival (Sato et al, 2003). Another issue is the increased radiation
dose of CT. The effective dose of CT of the chest, abdomen and
pelvis is 9.9mSv (Shrimpton et al, 2006), in comparison with a
bone scan (740MBq injected) at 4.2mSv (ICRP, 1988), and CXR at
0.02mSv (HPA, 2005). The long-term effects of radiation exposure
are a concern; however, this is likely to be less relevant in patients
with higher-stage breast cancer.
Out of 411 bone scans, 298 were negative, 52 were true positives
and 61 were false positives. These results are similar to findings of
Puglisi et al (2005) where 26 true-positive and 25 false-positive
results were reported in 412 breast cancer patients of all stages.
The false-positive rate of bone scans (13.7%) is much higher than
that of CT (3.8%) in our study. The increased specificity of CT may
reduce follow-up investigations, which could partially offset the
increased radiation dose, limit the psychological burden of false-
positive results and reduce the need for further invasive testing.
A meta-analysis of bone scan results in asymptomatic breast
cancer patients by the CCOPGI group revealed differences in
studies performed before 1980, with high pick-up rates, and those
after, with a low rate of metastatic detection (Myers et al, 2006).
The differences may be explained by differing thresholds for
reporting positive results. In current practice, any equivocal bone
scan result will lead to further imaging and possibly biopsy for
confirmation of malignancy; thus in the earlier studies it is
possible that some positive results were in reality false-positive
results. Also the advent of screening programmes is expected to
alter the demographics of the staging groups, with a higher
proportion of patients presenting with earlier stage disease. Similar
factors may help explain the relatively small incidence of
metastases observed in our patient population, with low-stage
disease: 0% of patients in stages 0 and I and only 0.3% of patients
in stage II shown to be true positives.
This study was not designed for direct comparison of test
accuracy, however, the apparent advantages of CT in relation to
improved sensitivity and patient convenience, along with the local
trend towards this form of imaging, have led us to recommend this
as the baseline imaging modality of choice in patients presenting
to our unit with asymptomatic newly diagnosed breast cancer.
Given the relative lack of evidence directly comparing CT and BS
for bone metastases in breast cancer, we are extending the CT
protocol in breast cancer patients to include the supraclavicular
fossa and proximal femur. The cost estimates in Table 4 are
included to give an indication of the relative costs of implementing
different imaging strategies based upon disease stage. Regardless
of which stage of disease is used as a cut-off for imaging, our data
suggest that implementing a strategy of using CT rather than
conventional staging investigations (CXR, BS and US) would result
in health-care cost saving.
CONCLUSION
The result of this study together with published evidence and
existing guidelines has led us to adopt the following policy for the
imaging of asymptomatic patients with newly diagnosed breast
cancer, which we hope will maximise metastatic detection while
minimising harmful side effects:
 Pre-operative CXR is not necessary as a staging investigation –
follow RCR guidelines (RCR, 2007)
 Patients with clinical stages III and IV disease (Greene et al,
2002) should undergo staging with CT of the chest (to include
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the supraclavicular fossa), abdomen and pelvis (including
proximal femur). This includes patients with tumours that are:
* Larger than 5 cm and involve at least one axillary lymph node
* Any size and involve X4 axillary lymph nodes
* Any size and involve at least one internal mammary,
infraclavicular or supraclavicular lymph node
* Any size and involve the skin or chest wall (includes
inflammatory breast cancer)
K In patients with stage III or IV disease where the results will not
affect management, staging investigations are not required
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